Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masakazu Kohda is active.

Publication


Featured researches published by Masakazu Kohda.


Journal of Biological Chemistry | 2009

Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva

Toru Fukuda; Masakazu Kohda; Kazuhiro Kanomata; Junya Nojima; Atsushi Nakamura; Jyunji Kamizono; Yasuo Noguchi; Kiyofumi Iwakiri; Takeo Kondo; Junichi Kurose; Ken-ichi Endo; Takeshi Awakura; Jun Ichi Fukushi; Yasuharu Nakashima; Tomohiro Chiyonobu; Akira Kawara; Yoshihiro Nishida; Ikuo Wada; Masumi Akita; Tetsuo Komori; Konosuke Nakayama; Akira Nanba; Yuichi Maruki; Tetsuya Yoda; Hiroshi Tomoda; Paul B. Yu; Eileen M. Shore; Frederick S. Kaplan; Kohei Miyazono; Masaru Matsuoka

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.


PLOS Genetics | 2016

A Comprehensive Genomic Analysis Reveals the Genetic Landscape of Mitochondrial Respiratory Chain Complex Deficiencies

Masakazu Kohda; Yoshimi Tokuzawa; Yoshihito Kishita; Hiromi Nyuzuki; Yohsuke Moriyama; Yosuke Mizuno; Tomoko Hirata; Yukiko Yatsuka; Yzumi Yamashita-Sugahara; Yutaka Nakachi; Hidemasa Kato; Akihiko Okuda; Shunsuke Tamaru; Nurun Nahar Borna; Kengo Banshoya; Toshiro Aigaki; Yukiko Sato-Miyata; Kohei Ohnuma; Tsutomu Suzuki; Asuteka Nagao; Hazuki Maehata; Fumihiko Matsuda; Koichiro Higasa; Masao Nagasaki; Jun Yasuda; Masayuki Yamamoto; Takuya Fushimi; Masaru Shimura; Keiko Kaiho-Ichimoto; Hiroko Harashima

Mitochondrial disorders have the highest incidence among congenital metabolic disorders characterized by biochemical respiratory chain complex deficiencies. It occurs at a rate of 1 in 5,000 births, and has phenotypic and genetic heterogeneity. Mutations in about 1,500 nuclear encoded mitochondrial proteins may cause mitochondrial dysfunction of energy production and mitochondrial disorders. More than 250 genes that cause mitochondrial disorders have been reported to date. However exact genetic diagnosis for patients still remained largely unknown. To reveal this heterogeneity, we performed comprehensive genomic analyses for 142 patients with childhood-onset mitochondrial respiratory chain complex deficiencies. The approach includes whole mtDNA and exome analyses using high-throughput sequencing, and chromosomal aberration analyses using high-density oligonucleotide arrays. We identified 37 novel mutations in known mitochondrial disease genes and 3 mitochondria-related genes (MRPS23, QRSL1, and PNPLA4) as novel causative genes. We also identified 2 genes known to cause monogenic diseases (MECP2 and TNNI3) and 3 chromosomal aberrations (6q24.3-q25.1, 17p12, and 22q11.21) as causes in this cohort. Our approaches enhance the ability to identify pathogenic gene mutations in patients with biochemically defined mitochondrial respiratory chain complex deficiencies in clinical settings. They also underscore clinical and genetic heterogeneity and will improve patient care of this complex disorder.


Journal of Human Genetics | 2007

Association of the HTRA1 gene variant with age-related macular degeneration in the Japanese population

Keisuke Mori; Kuniko Horie-Inoue; Masakazu Kohda; I. Kawasaki; Peter L. Gehlbach; Takuya Awata; Shin Yoneya; Yasushi Okazaki; Satoshi Inoue

AbstractThe purpose of this investigation was to determine whether the high-temperature requirement A-1 (HTRA1) gene polymorphism is associated with age-related macular degeneration (AMD) in native, unrelated Japanese patients. A total of 123 patients with AMD and 133 control subjects without AMD were recruited for this study. The single-nucleotide polymorphism (SNP) rs11200638 in the HTRA1 gene was assessed using a TaqMan assay. The risk A allele frequencies in the AMD cases and control patients were 0.577 and 0.380, respectively, and were associated with a significant risk of developing AMD (p=7.75×10−6). The results were more significant in subtype analyses with wet AMD (p=5.96×10−7). We conclude that the rs11200638 variant in the HTRA1 gene is strongly associated with AMD in the Japanese population. This result supports the hypothesis that the HTRA1 gene may increase susceptibility to AMD development and can participate in a potential new molecular pathway for AMD pathogenesis by extending this association across diverse ethnicities.


American Journal of Human Genetics | 2014

Mutations in GTPBP3 Cause a Mitochondrial Translation Defect Associated with Hypertrophic Cardiomyopathy, Lactic Acidosis, and Encephalopathy

Robert Kopajtich; Thomas J. Nicholls; Joanna Rorbach; Metodi D. Metodiev; Peter Freisinger; Hanna Mandel; Arnaud Vanlander; Daniele Ghezzi; Rosalba Carrozzo; Robert W. Taylor; Klaus Marquard; Kei Murayama; Thomas Wieland; Thomas Schwarzmayr; Johannes A. Mayr; Sarah F. Pearce; Christopher A. Powell; Ann Saada; Akira Ohtake; Federica Invernizzi; Eleonora Lamantea; Ewen W. Sommerville; Angela Pyle; Patrick F. Chinnery; Ellen Crushell; Yasushi Okazaki; Masakazu Kohda; Yoshihito Kishita; Yoshimi Tokuzawa; Zahra Assouline

Respiratory chain deficiencies exhibit a wide variety of clinical phenotypes resulting from defective mitochondrial energy production through oxidative phosphorylation. These defects can be caused by either mutations in the mtDNA or mutations in nuclear genes coding for mitochondrial proteins. The underlying pathomechanisms can affect numerous pathways involved in mitochondrial physiology. By whole-exome and candidate gene sequencing, we identified 11 individuals from 9 families carrying compound heterozygous or homozygous mutations in GTPBP3, encoding the mitochondrial GTP-binding protein 3. Affected individuals from eight out of nine families presented with combined respiratory chain complex deficiencies in skeletal muscle. Mutations in GTPBP3 are associated with a severe mitochondrial translation defect, consistent with the predicted function of the protein in catalyzing the formation of 5-taurinomethyluridine (τm(5)U) in the anticodon wobble position of five mitochondrial tRNAs. All case subjects presented with lactic acidosis and nine developed hypertrophic cardiomyopathy. In contrast to individuals with mutations in MTO1, the protein product of which is predicted to participate in the generation of the same modification, most individuals with GTPBP3 mutations developed neurological symptoms and MRI involvement of thalamus, putamen, and brainstem resembling Leigh syndrome. Our study of a mitochondrial translation disorder points toward the importance of posttranscriptional modification of mitochondrial tRNAs for proper mitochondrial function.


Genomics | 2010

Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model.

Hitomi Sudo; Atsushi B. Tsuji; Aya Sugyo; Masakazu Kohda; Chizuru Sogawa; Chisato Yoshida; Yoshinobu Harada; Okio Hino; Tsuneo Saga

Malignant mesothelioma is a highly aggressive tumor arising from serosal surfaces of the pleura and is triggered by past exposure to asbestos. Currently, there is no widely accepted treatment for mesothelioma. Development of effective drug treatments for human cancers requires identification of therapeutic molecular targets. We therefore conducted a large-scale functional screening of mesothelioma cells using a genome-wide small interfering RNA library. We determined that knockdown of 39 genes suppressed mesothelioma cell proliferation. At least seven of the 39 genes-COPA, COPB2, EIF3D, POLR2A, PSMA6, RBM8A, and RPL18A-would be involved in anti-apoptotic function. In particular, the COPA protein was highly expressed in some mesothelioma cell lines but not in a pleural mesothelial cell line. COPA knockdown induced apoptosis and suppressed tumor growth in a mesothelioma mouse model. Therefore, COPA may have the potential of a therapeutic target and a new diagnostic marker of mesothelioma.


American Journal of Human Genetics | 2015

COQ4 Mutations Cause a Broad Spectrum of Mitochondrial Disorders Associated with CoQ10 Deficiency

Gloria Brea-Calvo; Tobias B. Haack; Daniela Karall; Akira Ohtake; Federica Invernizzi; Rosalba Carrozzo; Laura S. Kremer; Sabrina Dusi; Christine Fauth; Sabine Scholl-Bürgi; Elisabeth Graf; Uwe Ahting; Nicoletta Resta; Nicola Laforgia; Daniela Verrigni; Yasushi Okazaki; Masakazu Kohda; Diego Martinelli; Peter Freisinger; Tim M. Strom; Thomas Meitinger; Costanza Lamperti; Atilano Lacson; Plácido Navas; Johannes A. Mayr; Enrico Bertini; Kei Murayama; Massimo Zeviani; Holger Prokisch; Daniele Ghezzi

Primary coenzyme Q10 (CoQ10) deficiencies are rare, clinically heterogeneous disorders caused by mutations in several genes encoding proteins involved in CoQ10 biosynthesis. CoQ10 is an essential component of the electron transport chain (ETC), where it shuttles electrons from complex I or II to complex III. By whole-exome sequencing, we identified five individuals carrying biallelic mutations in COQ4. The precise function of human COQ4 is not known, but it seems to play a structural role in stabilizing a multiheteromeric complex that contains most of the CoQ10 biosynthetic enzymes. The clinical phenotypes of the five subjects varied widely, but four had a prenatal or perinatal onset with early fatal outcome. Two unrelated individuals presented with severe hypotonia, bradycardia, respiratory insufficiency, and heart failure; two sisters showed antenatal cerebellar hypoplasia, neonatal respiratory-distress syndrome, and epileptic encephalopathy. The fifth subject had an early-onset but slowly progressive clinical course dominated by neurological deterioration with hardly any involvement of other organs. All available specimens from affected subjects showed reduced amounts of CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex activities. The pathogenic role of all identified mutations was experimentally validated in a recombinant yeast model; oxidative growth, strongly impaired in strains lacking COQ4, was corrected by expression of human wild-type COQ4 cDNA but failed to be corrected by expression of COQ4 cDNAs with any of the mutations identified in affected subjects. COQ4 mutations are responsible for early-onset mitochondrial diseases with heterogeneous clinical presentations and associated with CoQ10 deficiency.


PLOS ONE | 2014

A Genome-Wide Association Study for Diabetic Retinopathy in a Japanese Population: Potential Association with a Long Intergenic Non-Coding RNA

Takuya Awata; Hisakuni Yamashita; Susumu Kurihara; Tomoko Morita-Ohkubo; Yumi Miyashita; Shigehiro Katayama; Keisuke Mori; Shin Yoneya; Masakazu Kohda; Yasushi Okazaki; Taro Maruyama; Akira Shimada; Kazuki Yasuda; Nao Nishida; Katsushi Tokunaga; Asako Koike

Elucidation of the genetic susceptibility factors for diabetic retinopathy (DR) is important to gain insight into the pathogenesis of DR, and may help to define genetic risk factors for this condition. In the present study, we conducted a three-stage genome-wide association study (GWAS) to identify DR susceptibility loci in Japanese patients, which comprised a total of 837 type 2 diabetes patients with DR (cases) and 1,149 without DR (controls). From the stage 1 genome-wide scan of 446 subjects (205 cases and 241 controls) on 614,216 SNPs, 249 SNPs were selected for the stage 2 replication in 623 subjects (335 cases and 288 controls). Eight SNPs were further followed up in a stage 3 study of 297 cases and 620 controls. The top signal from the present association analysis was rs9362054 in an intron of RP1-90L14.1 showing borderline genome-wide significance (Pmet = 1.4×10−7, meta-analysis of stage 1 and stage 2, allele model). RP1-90L14.1 is a long intergenic non-coding RNA (lincRNA) adjacent to KIAA1009/QN1/CEP162 gene; CEP162 plays a critical role in ciliary transition zone formation before ciliogenesis. The present study raises the possibility that the dysregulation of ciliary-associated genes plays a role in susceptibility to DR.


Annals of clinical and translational neurology | 2015

Deficiency of ECHS1 causes mitochondrial encephalopathy with cardiac involvement.

Tobias B. Haack; Christopher B. Jackson; Kei Murayama; Laura S. Kremer; André Schaller; Urania Kotzaeridou; Maaike C. de Vries; Gudrun Schottmann; Saikat Santra; Boriana Büchner; Thomas Wieland; Elisabeth Graf; Peter Freisinger; Seila Eggimann; Akira Ohtake; Yasushi Okazaki; Masakazu Kohda; Yoshihito Kishita; Yoshimi Tokuzawa; Sascha Sauer; Yasin Memari; Anja Kolb-Kokocinski; Richard Durbin; Oswald Hasselmann; Kirsten Cremer; Beate Albrecht; Dagmar Wieczorek; Hartmut Engels; Dagmar Hahn; Alexander M. Zink

Short‐chain enoyl‐CoA hydratase (ECHS1) is a multifunctional mitochondrial matrix enzyme that is involved in the oxidation of fatty acids and essential amino acids such as valine. Here, we describe the broad phenotypic spectrum and pathobiochemistry of individuals with autosomal‐recessive ECHS1 deficiency.


Biochimica et Biophysica Acta | 2014

Diagnosis and molecular basis of mitochondrial respiratory chain disorders: Exome sequencing for disease gene identification

Akira Ohtake; Kei Murayama; Masato Mori; Hiroko Harashima; Taro Yamazaki; Shunsuke Tamaru; Y. Yamashita; Yoshihito Kishita; Yutaka Nakachi; Masakazu Kohda; Yoshimi Tokuzawa; Yumi Mizuno; Yohsuke Moriyama; Hidemasa Kato; Yasushi Okazaki

Mitochondrial disorders have the highest incidence among congenital metabolic diseases, and are thought to occur at a rate of 1 in 5000 births. About 25% of the diseases diagnosed as mitochondrial disorders in the field of pediatrics have mitochondrial DNA abnormalities, while the rest occur due to defects in genes encoded in the nucleus. The most important function of the mitochondria is biosynthesis of ATP. Mitochondrial disorders are nearly synonymous with mitochondrial respiratory chain disorder, as respiratory chain complexes serve a central role in ATP biosynthesis. By next-generation sequencing of the exome, we analyzed 104 patients with mitochondrial respiratory chain disorders. The results of analysis to date were 18 patients with novel variants in genes previously reported to be disease-causing, and 27 patients with mutations in genes suggested to be associated in some way with mitochondria, and it is likely that they are new disease-causing genes in mitochondrial disorders. This article is part of a Special Issue entitled Frontiers of Mitochondrial Research.


American Journal of Human Genetics | 2015

Intra-mitochondrial Methylation Deficiency Due to Mutations in SLC25A26

Yoshihito Kishita; Aleksandra Pajak; Nikhita Ajit Bolar; Carlo M.T. Marobbio; Camilla Maffezzini; Daniela Valeria Miniero; Magnus Monné; Masakazu Kohda; Henrik Stranneheim; Kei Murayama; Karin Naess; Nicole Lesko; Helene Bruhn; Arnaud Mourier; Rolf Wibom; Inger Nennesmo; Ann Jespers; Paul Govaert; Akira Ohtake; Lut Van Laer; Bart Loeys; Christoph Freyer; Ferdinando Palmieri; Anna Wredenberg; Yasushi Okazaki; Anna Wedell

S-adenosylmethionine (SAM) is the predominant methyl group donor and has a large spectrum of target substrates. As such, it is essential for nearly all biological methylation reactions. SAM is synthesized by methionine adenosyltransferase from methionine and ATP in the cytoplasm and subsequently distributed throughout the different cellular compartments, including mitochondria, where methylation is mostly required for nucleic-acid modifications and respiratory-chain function. We report a syndrome in three families affected by reduced intra-mitochondrial methylation caused by recessive mutations in the gene encoding the only known mitochondrial SAM transporter, SLC25A26. Clinical findings ranged from neonatal mortality resulting from respiratory insufficiency and hydrops to childhood acute episodes of cardiopulmonary failure and slowly progressive muscle weakness. We show that SLC25A26 mutations cause various mitochondrial defects, including those affecting RNA stability, protein modification, mitochondrial translation, and the biosynthesis of CoQ10 and lipoic acid.

Collaboration


Dive into the Masakazu Kohda's collaboration.

Top Co-Authors

Avatar

Yasushi Okazaki

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Akira Ohtake

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Kei Murayama

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Yoshihito Kishita

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Tomoko Hirata

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Yoshimi Tokuzawa

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Yosuke Mizuno

Tokyo Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroko Harashima

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge